Xiaodong Wang Sells 41,760 Shares of Beigene, Ltd. (NASDAQ:ONC) Stock

Beigene, Ltd. (NASDAQ:ONC) insider Xiaodong Wang sold 41,760 shares of the firm’s stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $223.50, for a total transaction of $9,333,360.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Xiaodong Wang also recently made the following trade(s):

• On Monday, April 14th, Xiaodong Wang sold 41,760 shares of Beigene stock. The shares were sold at an average price of $242.66, for a total transaction of $10,133,481.60.
• On Tuesday, March 18th, Xiaodong Wang sold 41,760 shares of Beigene stock. The shares were sold at an average price of $261.28, for a total transaction of $10,911,052.80.
• On Tuesday, March 4th, Xiaodong Wang sold 8,146 shares of Beigene stock. The shares were sold at an average price of $254.58, for a total transaction of $2,073,808.68.

Beigene Stock Performance

NASDAQ:ONC opened at $228.38 on Friday. The stock’s 50-day simple moving average is $243.42. The company has a market cap of $22.62 billion, a P/E ratio of -27.72, a price-to-earnings-growth ratio of 7.73 and a beta of 0.35. Beigene, Ltd. has a 52 week low of $141.31 and a 52 week high of $287.88. The company has a quick ratio of 1.72, a current ratio of 1.93 and a debt-to-equity ratio of 0.05.

Beigene (NASDAQ:ONC) last released its quarterly earnings data on Wednesday, May 7th. The company reported $1.22 EPS for the quarter, topping analysts’ consensus estimates of ($0.71) by $1.93. Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%. The company had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.12 billion. Sell-side analysts forecast that Beigene, Ltd. will post -5.82 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on ONC shares. TD Securities reiterated a “buy” rating and issued a $334.00 target price on shares of Beigene in a research note on Thursday, April 24th. Royal Bank of Canada reduced their price target on shares of Beigene from $312.00 to $311.00 and set an “outperform” rating for the company in a report on Thursday, May 8th. JPMorgan Chase & Co. increased their price target on shares of Beigene from $311.00 to $317.00 and gave the company an “overweight” rating in a report on Monday, April 21st. Guggenheim increased their price target on shares of Beigene from $348.00 to $350.00 and gave the company a “buy” rating in a report on Thursday, May 8th. Finally, JMP Securities set a $348.00 price objective on shares of Beigene in a report on Friday, February 28th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $319.00.

Beigene Company Profile

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.